C. L. Braal

Publications13
h-index5
Citations77
Highly Influential Citations2
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • R. Mathijssen
  • 428 Publications • 10,298 Citations
  • P. Neven
  • 984 Publications • 25,969 Citations
  • N. Turner
  • 304 Publications • 22,822 Citations
  • N. Harbeck
  • 1,190 Publications • 39,264 Citations
  • Publications
  • Influence
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
TLDR
The clinical pharmacokinetic and pharmacodynamic profiles of the three CDK4/6 inhibitors are reviewed and important future directions of the clinical applicability will be discussed.
The influence of cetomacrogol ointment processing on structure: A definitive screening design
A new method for the determination of total and released docetaxel from docetaxel‐entrapped core‐crosslinked polymeric micelles (CriPec®) by LC–MS/MS and its clinical application in plasma and…
Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.
TLDR
This study was amended in 2017 to explore endoxifen concentrations in relation to recurrence-free survival and was underpowered to draw solid conclusions on this end point, with a hazard ratio of 2.0 as input into their sample size calculations.
Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
TLDR
This study demonstrated the absence of a pharmacokinetic interaction between green tea supplements and tamoxifen, suggesting the use of green tea by patients with tamoxIFen does not have to be discouraged.
Quantification of ribociclib in dried blood spots by LC-MS/MS: Method development and clinical validation.
Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application.
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
TLDR
It is demonstrated that it is feasible to increase the percentage of patients with endoxifen levels ≥ 16 nM using therapeutic drug monitoring (TDM), and TDM is a safe strategy that offers the possibility of nearly halving the number of patientswith endoxIFen levels <16 nM.
Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer
TLDR
Concomitant intake of palbociclib with the moderate CYP3A4 inhibitor erythromycin resulted in an increase in palbokiclib AUC0–24h and Cmax of both 43%.
Factors Affecting Inter-individual Variability in Endoxifen Concentrations in Patients: Results From the Prospective TOTAM Trial
TLDR
The inter-individual variability of endoxifen concentration could largely be explained by CYP2D6 genotype and for a small proportion by age and weight, however, the remaining unexplained inter- individual variability is still high and therefore model-informed tamoxIFen dosing should be accompanied by therapeutic drug monitoring.
...
1
2
...